中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态主动,不招募
赞助商
Daiichi Sankyo, Inc.
合作者
SSS International Clinical Research GmbH

关键词

抽象

TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT, the burden of diffuse TGCT for patients (including pain, joint stiffness, swelling, reduced mobility and quality of life) or the economic impact of diffuse TGCT.
This study aims to collect data by an observational disease registry involving no intervention to the patient or changes to investigators treatment decisions.

描述

GCT is a rare, benign, but potentially locally aggressive and recurrent disease. Treatment pattern and treatment initiation, continuation or changes are solely at the discretion of the physician and the patient.

There will be no attempt to influence the prescribing patterns of any individual treating physician. All medication will be prescribed in the usual standard of care and will not be provided by the study sponsor.

Participation in the study will in no way influence payment or reimbursement for any treatment received by patients during the study.

It is the responsibility of the investigator and his study staff to enter all relevant patient data required for this registry in the electronic Case Report Form (eCRF) and in the patients' medical records.

Approximately 15 sites from up to 6 European Countries (France, Germany, Italy, The Netherlands, Spain and United Kingdom) and 4 sites from the US are planned to participate. The sites will be specialized sites that treat diffuse TGCT regularly.

日期

最后验证: 12/31/2019
首次提交: 10/23/2016
提交的预估入学人数: 10/25/2016
首次发布: 10/27/2016
上次提交的更新: 01/13/2020
最近更新发布: 01/17/2020
实际学习开始日期: 10/31/2016
预计主要完成日期: 03/31/2021
预计完成日期: 05/31/2021

状况或疾病

Giant Cell Tumors

-

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
取样方式Non-Probability Sample
接受健康志愿者
标准

Inclusion Criteria:

- Written informed consent for participation in the study (ICF)

- Patients with diffuse TGCT (diagnosed histologically) confirmed naïve or recurrent case

Exclusion Criteria:

- None

结果

主要结果指标

1. Percentage of participants with disease status reported as one of the categorical descriptions at Baseline [at Baseline]

Only patients with disease status reported as one of the five categorical descriptions below are included in this observation: fully active/able to carry on all pre-disease activities without restriction (0) restricted in physically strenuous activity, but ambulatory/able to carry out light or sedentary work (1) ambulatory (greater than [>] 50 percentage [%] of waking hours [h]), capable of all self care, but unable to carry out any work activities (2) capable of only limited self care, confined to bed/chair >50% of waking hours (3) completely disabled, cannot carry on any selfcare, totally confined to bed or chair (4) dead (5)

2. Percentage of participants with disease status reported as one of the categorical descriptions at 12 Months [at 12 Months]

Only patients with disease status reported as one of the five categorical descriptions below are included in this observation: fully active/able to carry on all pre-disease activities without restriction (0) restricted in physically strenuous activity, but ambulatory/able to carry out light or sedentary work (1) ambulatory (greater than [>] 50 percentage [%] of waking hours [h]), capable of all self care, but unable to carry out any work activities (2) capable of only limited self care, confined to bed/chair >50% of waking hours (3) completely disabled, cannot carry on any selfcare, totally confined to bed or chair (4) dead (5)

3. Percentage of participants with disease status reported as one of the categorical descriptions at 24 Months [at 24 Months]

Only patients with disease status reported as one of the five categorical descriptions below are included in this observation: fully active/able to carry on all pre-disease activities without restriction (0) restricted in physically strenuous activity, but ambulatory/able to carry out light or sedentary work (1) ambulatory (greater than [>] 50 percentage [%] of waking hours [h]), capable of all self care, but unable to carry out any work activities (2) capable of only limited self care, confined to bed/chair >50% of waking hours (3) completely disabled, cannot carry on any selfcare, totally confined to bed or chair (4) dead (5)

次要成果指标

1. Mean Number of Referrals or Specialist Visits to Assess the Health Resource Utilization in Patients with Diffuse TGCT through 24 Months [at Baseline, 12 Months, 24 Months]

Categories: Baseline, 12 Months, 24 Months

2. Mean Brief Pain Inventory (BPI) Average Interference Score From Baseline through 24 Months [Baseline, 6, 12, 18 and 24 months]

The BPI short form is a 5 minutes self administered questionnaire that assesses severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week. The change from baseline at each time point reflects the month X value minus the baseline value. The BPI average interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes). Categories (scores on a scale): at Baseline, at Month 6, at Month 12, at Month 18 and at Month 24

3. Mean Worst Stiffness Score from Baseline through 24 Months [Baseline, 6, 12, 18 and 24 months]

The Worst Stiffness numerical rating scale (NRS) is a one-item self-administered questionnaire assessing the "worst" stiffness in the last 24 hours. The NRS for this item ranges from 0 ("no stiffness") to 10 ("stiffness as bad as you can imagine"). Categories (scores on a scale): at Baseline, at Month 6, at Month 12, at Month 18 and at Month 24

4. Mean PROMIS Physical Function Score from Baseline through 24 Months [Baseline, 6, 12, 18 and 24 months]

PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures, developed by the US Department of Health and Human Services, that evaluates and monitors physical, mental, and social health. Physical function items relevant to the assessment of lower and upper limb function are to be selected from the PROMIS physical function item bank. Items assessing lower limb function will be administered to subjects with lower extremity tumors, and items assessing upper limb function will be administered to subjects with upper extremity tumors. The results from both sets of items will be combined and analyzed together. Categories (scores on a scale): at Baseline, at Month 6, at Month 12, at Month 18 and at Month 24

5. Mean Scores on the EuroQol Questionnaire (EQ) of 5 Dimensions (5D) on a Standardized 5-level (5L) Descriptive Health Status Scale (EQ-5D-5L), from Baseline through 24 Months [Baseline, 6, 12, 18 and 24 months]

The EQ-5D questionnaire is made up for two components; health state description and evaluation. The EQ-5D-5L is the health state description for measuring health status. The descriptive system comprises the 5 dimensions of mobility, self care, usual activities, pain/discomfort, and anxiety/depression. The participants self-rate each dimension on a 5-point, categorical scale: no problems, slight problems, moderate problems, severe problems, and extreme problems. Categories (scores on a scale): at Baseline, at Month 6, at Month 12, at Month 18 and at Month 24

6. Mean Scores on the EQ-5D Visual Analogue Scale (EQ VAS) Evaluation, from Baseline through 24 Months [Baseline, 6, 12, 18 and 24 months]

The EQ-5D questionnaire is made up for two components; health state description and evaluation. The EQ VAS is the evaluation that records the respondent's self-rated health on a 20 cm vertical, VAS with ends labeled "the best health you can imagine" and "the worst health you can imagine". Categories (scores on a scale): at Baseline, at Month 6, at Month 12, at Month 18 and at Month 24

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge